(0.18%) 5 108.92 points
(0.28%) 38 345 points
(0.01%) 15 929 points
(-0.32%) $83.58
(2.44%) $1.970
(-0.28%) $2 340.70
(-0.19%) $27.48
(2.66%) $946.65
(0.03%) $0.935
(-0.04%) $11.02
(-0.21%) $0.799
(1.62%) $93.36
3 days till quarter result
(amc 2024-05-02)
Expected move: +/- 6.68%
@ $9.72
发出时间: 15 Feb 2024 @ 02:10
回报率: -14.30%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 6.58 %
Live Chart Being Loaded With Signals
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus...
Stats | |
---|---|
今日成交量 | 34 589.00 |
平均成交量 | 1.05M |
市值 | 1.13B |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $-0.990 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.810 |
ATR14 | $0.0280 (0.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | De Backer Marianne | Sell | 72 995 | Common Stock |
2024-04-01 | Hanly Ann M. | Sell | 2 711 | Common Stock |
2024-03-27 | Lee Sung | Sell | 6 008 | Common Stock |
2024-02-22 | Hanly Ann M. | Buy | 32 500 | Common Stock |
2024-02-22 | Hanly Ann M. | Sell | 12 296 | Common Stock |
INSIDER POWER |
---|
-10.22 |
Last 98 transactions |
Buy: 8 177 990 | Sell: 9 772 896 |
音量 相关性
Vir Biotechnology Inc 相关性 - 货币/商品
Vir Biotechnology Inc 财务报表
Annual | 2023 |
营收: | $86.18M |
毛利润: | $63.96M (74.22 %) |
EPS: | $-4.59 |
FY | 2023 |
营收: | $86.18M |
毛利润: | $63.96M (74.22 %) |
EPS: | $-4.59 |
FY | 2022 |
营收: | $1.58B |
毛利润: | $1.43B (90.74 %) |
EPS: | $3.89 |
FY | 2021 |
营收: | $1.10B |
毛利润: | $1.03B (93.99 %) |
EPS: | $4.44 |
Financial Reports:
No articles found.
Vir Biotechnology Inc
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。